ANAVEX 19-144

ANAVEX 19-144 is a small molecule sigma-1 receptor agonist developed by Anavex Life Sciences Corp. for the treatment of neurodegenerative and neurodevelopmental disorders. It is the primary active demethyl metabolite of blarcamesine (ANAVEX 2-73), which functions as a prodrug for ANAVEX 19-144. The compound exhibits neuroprotective properties and has demonstrated efficacy in preclinical models of Alzheimer's disease and learning impairments. Notably, ANAVEX 19-144 has an elimination half-life of approximately 21.45 hours, which is roughly double that of its parent compound, allowing for extended and sustained activation of the sigma-1 receptor. The compound is also being explored for potential therapeutic applications in treating insomnia, anxiety, and agitation, supported by patent coverage extending until at least 2037.

Other names

demethyl-ANAVEX 2-73demethyl-ANAVEX2-73demethyl-ANAVEX-2-73demethyl-blarcamesine